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Abstract
Graves’ disease is an autoimmune organ specific disease characterized by  
excessive production of hormones from the thyroid gland and by its diffuse 
enlargement. The growth and function of the thyroid gland are stimulated by 
autoantibodies directed against the thyroid-stimulating hormone receptor. 
Pregnancies complicated by Graves’ disease are characterized with higher incidence 
of abortion, preterm delivery, low-birth- weight infants and neonatal mortality, as 
well as maternal complications such as heart failure, eclampsia and rarely thyroid 
storm. When fully controlled hyperthyroidism have excellent outcomes. Different 
therapeutic approaches are used in women with Graves’ planning pregnancy and 
in those when the disease is diagnosed after they became pregnant. Thionamides 
are the first choice for treatment, with Propylthyouracil being preferred for the 
first trimester and Methimazole for the second and third trimester. Aplasia cutis 
and some other malformations were associated with methimazole use during 
pregnancy. Monitoring the effect of treatment should ensure keeping maternal 
FT4 in the high normal range. Block-and replace regimen is not recommended and 
rdioiodine therapy is absolutely contraindicated. Thyroidectomy may be considered 
before pregnancy or in rare cases in the second trimester. Iodine is avoided because 
of the risk of fetal hypothyroidism and goiter. The use of beta-blockers is contro-
versial. Noenatal thyrotoxicosis may occur in association with maternal Graves’ 
disease due to maternal TSAbs cross through the placenta.
Keywords: Graves’ disease, pregnancy, thionamides, iodine, surgery
1. Introduction
Graves’ disease (GD) is an autoimmune organ specific disease characterized 
by excessive production of hormones from the thyroid gland (hyperthyroidism) 
and by its diffuse enlargement. The growth and function of the thyroid gland are 
stimulated by autoantibodies directed against the thyroid-stimulating hormone 
(TSH) receptor (TSHR). Nevertheless, other autoantibodies against thyroid 
peroxidase (TPO) and thyroglobulin (Tg) may also be present, TSHR is the major 
autoantigen of Graves’ disease, making antibodies against it (TRAb) the most 
characteristic for the disease. Graves’ disease (GD) is the most frequent cause of 
thyrotoxicosis in iodine sufficient countries [1], although the exact frequency of 
GD in general population is difficult to be established and differs from country to 
country. A meta-analysis of various studies has estimated the general prevalence 
of GD to be around 1% [2], which makes it one of the most frequent clinically 
relevant autoimmune disorders. Graves’ disease is a multifactorial disorder. Like 
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all autoimmune diseases, GD is characterized with the loss of immune tolerance 
to thyroid antigens and the initiation of a sustained autoimmune reaction caused 
by a complex interplay of genetic, hormonal and environmental factors. While 
detailed discussion of these factors is beyond the scope of this chapter, it is worth 
to mention that GD is typically a disease of women, with the female-to- male ratio 
ranges in different studies from 5 to 10 at any age [2, 3]. Autoimmune disorders are 
in general more prevalent in women and genetic and nongenetic factors may play 
role for that [4, 5]. Male hormones are considered to down-regulate immunity and 
thus play a protective role from autoimmunity, whereas the effect of estrogen is not 
always unequivocal [4, 5]. Despite this, little evidences in the literature are backing 
the role for sex hormones in the high prevalence of GD in women. Moreover thyroid 
autoimmunity often accompanies patients with Turner’s syndrome, who have low 
estrogen levels [6]. Besides sex hormones, some genetic factors linked with the X 
chromosome could explain the epidemiologic evidence of a female preponderance 
in GD. In families with GD, a putative Graves’ disease susceptibility locus on the 
long arm of X chromosome was located by an linkage analysis [7]. Inactivation of 
the X chromosome, an epigenetic phenomenon, has been suggested to determine 
the female predisposition to thyroid autoimmunity. One study showed that this 
phenomenon is more frequently observed in patients with GD or autoimmune 
thyroiditis than in healthy controls [8]. Never mind, what the predisposing factors 
for GD could be, pregnancy, itself, is a well-known risk factor for thyroid autoim-
munity. Pregnancy can influence and change the course of a pregestational Graves’ 
disease or can become a reason for the development of GD during the pregnancy or 
after delivery. The risk of development of GD in postpartum year increases fourfold 
to eightfold [9]. The reasons for this could be explained by the observed abrupt fall 
in the level of pregnancy-associated immunosuppressive factors immediately after 
delivery (rebound immunity) [9]. The factors involved in the immune alterations 
of the postpartum period may include, but are not limited to estrogen and progestin 
[9, 10]. Approximately 2–3% of all pregnancies are complicated by thyroid disease 
[11], making thyroid disorders the second most common significant pathology 
affecting women during pregnancy after diabetes mellitus [12]. Detailed under-
standing of the physiology, pathophysiology, diagnosis and treatment is required to 
limit the effects on both maternal and fetal health.
2. Physiology of maternal and fetal thyroid in pregnancy
Pregnancy induces several major changes to thyroid morphology and physiol-
ogy. Diagnosis of thyroid dysfunction during pregnancy is complicated by the 
hormonal changes that take place, posing specific challenges for both detection 
and management. During pregnancy, thyroid gland physiologically undergoes 
moderate enlargement, typically increasing in size between 10 and 40% of 
volume, and increasing of vascularization. This enlargement can be more pro-
nounced if there is underling iodine deficiency [13]. At the same time there are 
transient, reversible after delivery, changes in thyroid hormone physiology and 
iodine metabolism. In early gestation, the thyroid gland is stimulated not only 
by TSH, but also by the alpha subunit of human chorionic gonadotropin (hCG), 
produced by the syncytiotrophoblasts of the developing placenta, which binds 
to and stimulates the TSH receptor, increasing thyroid hormone production and 
resulting in a subsequent reduction in serum TSH concentration [14]. Normally, 
hCG starts to rise from the very beginning of pregnancy and peaks at around 
9–11 weeks of gestational age. Due to this, there is a parallel decrease in serum 
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TSH in the first trimester. Generally, TSH concentrations in pregnant women are 
lower than in non-pregnant women. Physiologically TSH concentrations fluctuate 
during different periods of gestation. During the first trimester, approximately 
15% of healthy women have TSH level below the lower limit of the reference 
range of 0.4 mU/L [15, 16]. The percentage of women with suppressed TSH falls 
to about 10% in the second trimester, and 5% in the third trimester [17]. The 
upper limit of TSH reference range during pregnancy is also decreased by about 
0.5–1.0 mU/L, in comparison to the typical nonpregnant TSH reference range and 
this downward shift usually occurs in the latter first trimester of pregnancy but 
typically not before week 7 [18]. Levels of hCG then decline until approximately 
20 weeks of gestation and remain stable for the remainder of the pregnancy [19], 
which is followed by a slight increase of TSH levels. The level of decrease of TSH 
depends on number of the developing fetuses, because hCG concentrations are 
higher in multiple pregnancies than in singleton pregnancies, and downward 
shift in the TSH reference interval is greater in twin pregnancies [20]. The degree 
of the lowering of TSH concentrations during pregnancy varies significantly 
between different racial and ethnic groups, that is why the recommended by 
American Thyroid Association (ATA) trimester-specific reference ranges for 
TSH levels shown on Table 1 [21], require determination of population-based 
trimester-specific reference ranges for serum TSH through assessment of local 
population data.
The reduction of the lower TSH reference range, observed during pregnancy 
should be regarded in the light of the data that even if this represents an undergoing 
subclinical hyperthyroidism, it has not been associated with adverse pregnancy 
outcomes. In a small percentage of women, TSH can be undetectable (<0.01 mU/L), 
but this is still represent a normal pregnancy. Therefore, a maternal TSH concentra-
tion that is low but detectable is likely not to be clinically significant [22].
Starting from the fourth week of gestation, the increase of estrogens causes 
the rise of circulating level of thyroid-binding globulin (TBG). Estrogens induce 
increase in the sialylation of the TBG, which is followed by a decrease of its hepatic 
clearance and by a prolongation of its serum half-life from 15 minutes to 3 days in 
comparison with the nonpregnancy time. TBG level reaches a plateau during mid-
gestation and remain elevated until delivery. In the postpartum period TBG tend to 
normalize [23]. This rise of TGB level is followed by an increase of the total concen-
trations of thyroxine (TT4) and of triiodothyronine (TT3) in early pregnancy. There 
levels achieve a plateau early in the second trimester, at a concentrations value of 
30–100% greater than prepregnancy [24]. To continue to maintain normal unbound 
thyroid hormone levels, thyroid gland needs to increase its thyroid hormone pro-
duction. Some studies have reported a decrease, whereas others have stated even an 
increase of free T4 (FT4) and T3 (FT3) making the changes in free-hormone levels 
during pregnancy controversial. Despite this, pregnant women in general have lower 
free-hormone concentrations at term than nonpregnant women [17, 25, 26]. Because 
TSH range
First trimester >0.1 mIU/L and < 2.5 mIU/L
Second trimester >0.2 mIU/L and < 3.0 mIU/L
Third trimester >0.3 mIU/L and < 3.0 mIU/L
TSH, thyroid-stimulating hormone.
Table 1. 
Generalized trimester-specific reference ranges for TSH levels [21].
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FT4 reference intervals in pregnancy vary widely between methods, interpretation 
of FT4 values requires method-specific as well as trimester-specific ranges.
The placenta is also an active player in thyroid hormone metabolism. It is a 
site for the inner ring deiodination of T4 and T3, generating the inactive iodo-
thyronines, reverse T3 and 3,3′-T2, respectively, and thus modulating the amount 
of active hormone that passes to the fetus [27]. Because of the increased thyroid 
hormone requirements and iodine glomerular filtration rate during pregnancy [28], 
adequate iodine availability is strongly necessary to meet these needs. In iodine-
replete regions, women are able to meet the increased demands of pregnancy. If 
adequate iodine is not available, TSH rises and consequently goiter develops [29]. 
Thyroid hormones play a vital role in the early embryogenesis. They are essential 
for neurodevelopment, somatic growth, and tissue differentiation. Because, 
organogenesis of fetal thyroid gland occurs by around 12-th week of gestation and 
the gland becomes functionally active approximately eight weeks later by the 20-th 
week of gestation, till then, the fetus fully relay on maternal T4, which is the only 
thyroid hormone that can cross the placenta. Fetal deiodinase converts maternal T4 
to the bioactive T3The [30].
After his thyroid gland becomes active and starts to produce hormones, fetal 
thyroidal turnover of iodine increases and becomes much higher than that in adults 
[30]. Fetal iodine store, which exclusively depends from maternal intake, must be 
continuously refilled. Iodine homeostasis, following fluctuating metabolic needs 
varies across the different trimesters. After parturition, maternal iodine continues 
to be the only source of iodine to the breast-fed neonate. Sodium Iodine symporter 
(NIS) is present in breast tissue and is responsible for concentrating iodine in 
colostrum and breast milk [31].
3. Thyroid autoimmunity in pregnancy
In around 10% of the women with childbearing potential thyroid antibod-
ies could be found and they represents the most common autoimmune disease. 
Stagnaro-Green et al. in 1990 first demonstrated an association between pregnancy 
loss and thyroid antibodies. They showed, that there was a 2-fold increase in the 
risk of pregnancy loss (17% vs. 8.4%) in women with thyroid antibodies [32]. 
One meta-analysis discovered, that the presence of thyroid antibodies in pregnant 
women was connected with a 4-fold increased risk of miscarriage in cohort studies, 
and a 1.8-fold increased risk in case–control studies [33]. The association of thyroid 
autoimmunity and preterm birth is not unambiguously as the studies showed 
conflicting results. Some found significant association [33–36], while others [37] 
didn’t show such correlation.
Following the changes of the activity of the immune system through pregnancy, 
the activity of Graves’ disease fluctuates. Concomitant changes of the TSH receptor 
antibody (TRAb) levels, generally reflecting the clinical course of the disease, are 
observed [38]. During the first trimester TRAb levels are usually elevated with a 
subsequently fall to even undetectable values during the second and third trimes-
ters and may increase again postpartum [39, 40]. Due to this pattern of fluctuations 
of TRAb levels, exacerbation of the clinical symptoms of Graves’ disease may occur 
in the first trimester of gestation, followed by a remission in the second and third 
trimesters, because of the observed immune tolerance [41]. The decrease in TRAb 
levels, rather than increases in inhibitory anti-TSH receptor antibodies determines 
this clinical pattern [39]. From a clinician’s point of view, the dosage of antithyroid 
drugs can be reduced or even discontinued late in gestation and restarted in the 
postpartum period [41].
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4. Hyperthyroidism and pregnancy
Hyperthyroidism is defined as an excessive production of thyroid hormones 
caused by immune or nonimmune thyroid disease. Hyperthyroidism is less com-
mon than hypothyroidism, but nevertheless, it represents a great challenge for the 
physician, pregnant woman and developing fetus. Specific knowledge is required by 
healthcare providers and a team approach is necessary to provide the best possible 
cares for pregnant women with GD. Caring physicians (gynecologists, endocrinolo-
gists, cardiologists) must be aware of the symptoms of thyrotoxicosis, often over-
lapping with the pregnancy itself and of specific changes of the thyroid hormones 
during pregnancy. Knowing the fact, that any pregnancy complicated with hyper-
thyroidism carries a greater risk for complications for both mother and developing 
fetus, proper diagnosis and treatment are necessary. Adequate decisions about when 
to start treatment and with what to start are required, following the ancient princi-
ple of primium non nocere. Although our therapeutic approaches didn’t change very 
substantially during the last fifty years, our understanding of the pathophysiology, 
hormonal changes, immunology and obstetric outcomes have changed dramatically. 
We still have at our disposal only two types of antithyroid drugs (ATD) (see later in 
the text), which are the same that had been in use since the 1950’s and still remain 
the cornerstone of treatment of GD in pregnancy. Rarely, other approaches are 
necessary, like surgery during the second trimester. Radioiodine ablation is abso-
lutely contraindicated. Close monitoring of thyroid hormone levels and frequent 
adjustment of the dose are necessary to avoid both overdosage or subdosage of 
antithyroid drugs.
The reasons for thyrotoxicosis during pregnancy can be divided in such 
typical for all patients and such specific for the pregnancy. The common causes 
for thyrotoxicosis include: Graves’ disease, chronic thyroiditis, painless thy-
roiditis, subacute thyroiditis, toxic adenoma, multinodular goiter; excessive 
levothyroxine (LT4) intake and drug induced thyrotoxicosis caused by iodine, 
amiodarone, lithium. The causes of thyrotoxicosis specific for the pregnancy are: 
gestational transient thyrotoxicosis, multiple gestations, trophoblastic disease, 
hyperplacentosis, hyperreactio luteinalis [22]. Grave’s disease and gestational 
transient thyrotoxicosis (GTT) account for the majority of hyperthyroidism in 
pregnancy. Graves’ disease affects 0.2% of pregnant women [42]. Thyrotoxicosis 
during pregnancy could affect both pregnant woman and developing fetus. 
Hyperthyroidism may cause both maternal complications such as heart failure, 
eclampsia and thyroid storm and also higher incidence of abortion, preterm 
delivery, low-birth-weight infants and neonatal mortality [43]. Distinguishing 
between different causes of hyperthyroidism is relevant, because some of them, 
like GTT, are transient, lead to mild thyrotoxicosis and do not require treatment 
with antithyroid drugs and are not associated with adverse pregnancy outcomes 
[44]. The Endocrine Society recommends that screening for thyroid conditions 
in pregnancy is performed in women >30 years, those with previous personal or 
family history of thyroid disease, women with issues with conception and existing 
autoimmune conditions [45].
5. Graves’ disease and pregnancy
As it has been already discussed, generally there are three scenarios in which 
Graves’ disease may affect a pregnancy. First, women with preexisting active 
Graves’disease. Second, women in remission, who may experience a relapse during 
pregnancy. Third, Graves’ disease may occur for the first time during gestation [46]. 
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The women with prepregnancy active disease (either treated or untreated) may 
undergo exacerbation during the first trimester. Those, with previously diagnosed 
GD, who stayed in clinical remission and remained euthyroid throughout the whole 
pregnancy, hyperthyroidism may recur in the postpartum period. We must be very 
careful in this situation, because this may represent either the thyrotoxic phase of 
postpartum thyroiditis (PPT) or in up to 25% or relapse of Graves’ disease. Even in 
those with PPT, Graves’ disease may recur after resolution of PPT, triggered by the 
destruction of the thyrocytes [47].
5.1 Diagnosis
Diagnosis should begin with taking complete case history, medical history 
and family history. The clinical diagnosis of hyperthyroidism may be difficult 
because pregnancy is itself a hypermetabolic state with symptoms of palpitations 
and heat intolerance. In addition, patients will usually have increased irritability, 
decreased exercise tolerance, heat intolerance, fatigue and increasing shortness 
of breath during physical activity. The examination usually reveals the presence 
of a diffuse goiter, sometimes with a bruit or thrill and eye changes. The clinician 
must recognize this constellation of symptoms so that the patient can be appro-
priately screened for hyperthyroidism. Once, hormonally hyperthyroidism has 
been established, it is very important to go deeper into the specific reason which 
causes it, because all types of thyrotoxicosis are characterized with similar changes 
of thyroid hormones. Different reasons for hyperthyroidism during pregnancy 
require different therapeutic approaches. Some are self-limiting and do no require 
treatment with ATD but only follow up.
5.2 Differential diagnosis
The most common cause of nonautoimmune hyperthyroidism is gestational 
transient thyrotoxicosis (GTT), defined as transient hyperthyroidism, limited 
to the first trimester of pregnancy. It is associated with hyperemesis gravidarum 
(HG) and is characterized by elevated serum FT4 and suppressed or undetect-
able serum TSH. It is differentiated from Graves’ disease by the absence of anti-
TSH-receptor antibody (TRAb) [48]. Hyperemesis gravidarum often presents 
in the first trimester of pregnancy with severe nausea and vomiting [49]. It may 
result in dehydration and ketonuria. Thyroid hormones return to their normal 
trimester specific reference ranges within 15 weeks, due to resolution of vomit-
ing. Initially FT4 normalized spontaneously; however, serum TSH may remain 
suppressed for several other weeks and does not require ATD therapy, because 
this condition is self-limiting [50]. Rarely, for example in the case of dual or 
triple pregnancy, connected with very high level hCG, the use of ATD is required 
due to the severity of symptoms. For the clinical practice, it is very important to 
differentiate between GTT and Graves’ disease. The presence of goitre, thy-
roid eye disease (Graves’ orbitopathy) and TRAbs in Graves’ disease and their 
absence in GTT can help for proper diagnosis. Because in both conditions there 
are similar changes of TSH (low) and FT4(high) levels, using a free T3/free T4 
ratio could be discriminatory. Often the patients with gestational thyrotoxicosis 
have significantly lower or even normal T3 values [51].
Subclinical hyperthyroidism, defined as a serum TSH concentration below the 
lower limit of reference range, with FT4 and FT3 concentrations within normal 
reference range, affects up to 1.7% of pregnant women. This condition has not 
been found to be associated with adverse outcomes and doesn’t require ATD 
therapy [31].
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5.3 Laboratory
The usual findings from the laboratory studies show low, below the trimester-
specific 95% lower confidence limit, TSH level together with elevated serum thy-
roid hormone (FT4 and FT3) concentrations. We should always consider the fact 
that up to 50% of women with hyperemesis gravidarum may have similar changes 
of theh hormonal levels (suppressed serum TSH level and/or elevated FT4) [52]. 
An elevated free T3 index or free T3 level may be the most clinically useful test to 
distinguish hyperthyroid patients from those with hyperemesis gravidarum as less 
than 15% of hyperemetic women have elevations in these measures. TSH receptor 
antibodies are usually detectable and may also be of diagnostic utility. High levels of 
TRAb cross placental barrier [53]. and the risk of fetal and neonatal thyrotoxicosis 
increases with TSRAb values 3–5 times above normal [54, 55].
5.4 Pregnancy outcomes
Maternal hyperthyroidism is associated with increased morbidity for both 
mother and fetus. Prior to the development of ATD, only about 50% of hyperthy-
roid women were be able to conceive. About in half of those who conceived, sponta-
neous miscarriage and premature delivery occurred [56]. The degree and duration 
of hyperthyroidism strongly correlate with pregnancy outcomes for both mother 
and fetus. The highest risk was reported in those with uncontrolled or poorly 
controlled disease and a decreased risk in those appropriately treated with ATD. 
Established thyrotoxicosis during gestation or before a planned pregnancy, requires 
appropriate treatment, because in cases with uncontrolled maternal hyperthyroid-
ism in the first trimester, the period of embryogenesis, there is an increased risk for 
congenital malformations (imperforate anus, polydactyly, harelip) [57]. The use of 
ATD during this period itself is not associated with a higher incidence of structural 
anomalies. For optimal pregnancy outcomes it is very important to keep maternal 
hyperthyroidism under control, avoiding the development of drug induced hypo-
thyroidism, understanding the crucial significance of thyroid hormones for the 
normal embryogenesis. Significantly, subclinical hyperthyroidism, has not been 
found to be associated with adverse pregnancy outcomes and doesn’t require anti-
thyroid therapy [22]. Pregnancy complications reported in hyperthyroid women 
vary in frequency in different studies and include: miscarriage from 8 to 10–21% 
[58, 59], preterm delivery [58, 60, 61] from 3 to 14% to 21–88%, preeclampsia [60] 
from 2–11%, heart failure [61] from 3–63%, stillbirth [58, 61] from 0% -7 to 50%, 
small for gestational age [59, 62] and thyroid storm during delivery.
5.5 Treatment
Unfortunately, because the cause of the immune dysregulation in Graves’ disease 
remains unclear, the available treatments are directed at the thyroid gland rather 
than the underlying autoimmunity. In general, the available therapies include: 
Antithyroid drugs, surgery and radioiodine, with predominant use of ATD in 
pregnancy hyperthyroidism, surgery in exception, during the second trimester and 
iodine ablation being absolutely contraindicated. Because the degree of hyperthy-
roidism can vary from patient to patient, those who are relatively asymptomatic 
may remain undiagnosed and untreated till the delivery, when usually aggravation 
of thyrotoxicosis is observed. Even when they had been properly diagnosed, they 
may do not want to accept the diagnosis and ask whether specific treatment is 
really necessary, fearing of possible side effects of the drugs both for them and for 
their developing fetuses. Usually they consider their complaints to be related with 
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the pregnancy itself. Those with overt hyperthyroidism require restoration of a 
euthyroid state because of potentially negative outcomes, both for the mother and 
the fetus. Fully controlled hyperthyroidism substantially decrease the potential risk 
for these negative outcomes and at the same time is not a reason for recommending 
abortion.
Therapeutic approaches differ from case to case. In the first scenario, when GD 
is preceding pregnancy, the woman will be advised to conceive after restoration of 
euthyroidism. Taking into account patent’s plan for the time of the future preg-
nancy, treatment with thionamide drugs is started, and the treatment continues 
throughout the whole pregnancy. In this case, the patient should be fully aware 
of the possible side effects of ATD, both for the mother and fetus and of the need 
for frequent monitoring of thyroid hormones levels. To avoid this an if the woman 
with GD is willing to postpone her future pregnancy, than alternatively radioio-
dine ablation can be offered. Pregnancy should be delayed for at least 4 months 
after radioiodine therapy, but a longer period, 6 months or even a year, is usually 
required for restoring euthyroid state and establishing the necessary stable dose of 
the inevitable postablational replacement therapy with thyroid hormones. Surgery 
may also be considered as an alternative because of more rapid restoration of 
euthyroidism.
In the second scenario, if GD is diagnosed during pregnancy, ATD are almost the 
only therapeutic option. Radioiodine is absolutely contraindicated, because it may 
result in congenital hypothyroidism and may cause malformations. Thyroidectomy 
is restricted to exceptional cases.
In the third scenario, if GD is established after delivery and when the possibility 
of transient, self-limiting destructive thyrotoxicosis has been excluded, it is pru-
dent to start thionamide treatment. In this case breast feeding should be stopped, 
because of the risk for development of neonatal hypothyroidism (see below). 
Radioiodine ablation with its delayed effect of achieving euthyroidism, the need 
for concomitant use of ATD to control symptoms in some cases and the need for 
isolation for several days, usually is not well accepted by the mothers. Surgery is an 
option in patients who experienced side effects of ATD use, or found it difficult to 
adhere to the prescribed drugs, either due to the number of pills or to the frequency 
of their intake.
Decision to initiate ATD treatment depends on the severity of the clinical symp-
toms and the pretreatment levels of FT4, FT3 and TSH. In mild cases with Graves’ 
disease, when FT4 values are at or slightly above the reference range, treatment may 
be withheld with a subsequent monitoring of the thyroid status as long as there 
is a satisfactory clinical progression of pregnancy. In other words, the pregnant 
woman with Graves’ disease should be kept in slight subclinical hyperthyroidism, 
because there are no reported gestational adverse effects of maternal subclinical 
hyperthyroidism [63]. The goal of treatment is to keep the patient euthyroid, using 
the lowest possible dose of antithyroid drugs necessary to maintain FT4 levels in the 
upper one-third of the normal non pregnant range or up to 10% above the normal 
range [64]. This level will ensure fetal euthyroidism, because FT4 in the mother’s 
serum correlates with fetal FT4 levels in cord blood [65]. Maternal serum T3 levels 
may not be as helpful because there is no correlation with fetal thyroid function 
[66] The dose should be adjusted every 2–4 weeks to maintain a serum FT4 of 1.7 to 
2.0 ng/L and TSH at or just below at the 95% confidence interval trimester-specific 
lower limit [67]. The presence of detectable TSH is an indication to decrease ATD 
dose [60]. A low TSH level is not a reliable index to judge the adequacy of treat-
ment, because it doesn’t promptly reflect the changes in thyroid function like FT4. 
It is important to monitor TSH level, because a high level always indicates over 
dosage of ATD and the need for proper dosage correction of the drugs. Because of 
9
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the expected immunosuppression during the second and third trimester, a partial 
and transient remission of Grave’s disease may occur and appropriate reduction 
of the dose or even discontinuation of ATD could be done. Otherwise excessive 
doses of ATDs, indeed, may affect fetal thyroid function, with the development of 
hypothyroidism and/or goiter [68, 69]. Relapse of the hyperthyroidism is frequent 
in postpartum period [70].
5.5.1 Antithyroid drugs
ATD are the first choice for treatment of Graves’ disease during pregnancy. 
Propylthiouracil (PTU) and methimazole (MMI) are equally effective in the man-
agement of hyperthyroidism during pregnancy. Propylthiouracil and methimazole 
inhibit thyroid hormone synthesis by interfering with intrathyroidal iodine utiliza-
tion and the iodotyrosine coupling reaction, both of which are catalyzed by thyroid 
peroxidase. Antithyroid drugs do not directly affect iodine uptake or hormone 
release by the thyroid. Because of this, the clinical and hormonal improvement 
is delayed for 10-14 days after their implementation in the therapeutic regimen. 
PTU, but not methimazole, inhibits the conversion of T4 to T3 in peripheral tis-
sues, thus theoretically it can ensure faster alleviation of the symptoms and reach-
ing the desired levels of FT4. In clinical practice this is not considered relevant. 
Comparative study showed that methimazole generally normalizes serum T4 and 
T3 levels faster than PTU [71]. Both antithyroid agents are well absorbed from the 
gastrointestinal tract. They differ in their ability to bind to proteins in circulation, 
with PTU being strongly protein-bound, mainly to albumin, at physiologic pH, 
while methimazole binding to proteins is negligible [72]. Other studies have found 
that both drugs readily cross the placenta [73, 74]. The serum half-lives of PTU 
and methimazole are 1 and 4 to 6 hours, respectively. The intrathyroidal duration 
of action of both drugs is longer than that. Both drugs are metabolized in the liver 
and their metabolites are excreted by the kidney. However, so far there are no data, 
that the doses used to treat hyperthyroidism generally need to be altered in patients 
with liver or kidney disease. This characteristic, apart from their side effects, may 
determine the choice of the antithyroid drug in pregnancy and lactation, since 
PTU crosses the placenta and breast epithelium less readily than methimazole. So 
it is reasonable to begin therapy with PTU because there are no reported cases of 
PTU-associated aplasia cutis. However, if a woman cannot tolerate PTU for any 
reason, experience side effects does not want to take the prescribed number of pills 
(PTU usually requires multiple daily dosages, whereas MMI can often be given 
once daily), MMI may be substituted. The initial dose rarely exceeds more than 
450 mg of PTU or 30 mg of MMI daily in order to achieve the predefined levels 
of FT4 and TSH. The median time, usually seven to eight weeks, to normalization 
of the maternal FT4 index for both PTU and MMI is equal [75], but improvement 
in these parameters may be seen earlier at three to four weeks. This fact, makes 
clinically relevant to reassess maternal FT4 or total T4 at an interval of three to four 
weeks and to adjust ATD dosage appropriately based upon the current levels of 
thyroid hormones. We should keep in mind, that maternal serum TSH levels may 
remain suppressed for several weeks after normalization of thyroid hormone levels. 
So measuring TSH level is not helpful early in treatment, and may mislead us to 
continue with the unnecessary high dose of ATD, causing drug induced hypothy-
roidism and thus depriving the developing fetus from crucially important maternal 
T4 delivery. As was discussed above, due to the changes of the activity of Graves’ 
disease throughout pregnancy, determined by fluctuations of TRAbs concentra-
tions, in the late second and third trimesters the dose of ATD can be reduced or 
even stopped by 32 to 34 weeks of gestation in 30% of women [76]. Of course, the 
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same spectrum of adverse effects related to ATD therapy in the nonpregnant state 
applies to use during gestation.
Both drugs are showing similar fetal outcomes, in terms of thyroid function. 
The risk for congenital abnormalities had been considered to be higher in MMI 
than in PTU.
Aplasia cutis and also other malformations have been reported in the offspring 
of mothers who had taken methimazole during pregnancy [67, 77]. Aplasia cutis is 
a congenital localized absence of skin that occurs spontaneously in approximately 
1 in 2000 births [78]. Many years, the fear from the possible development of this 
complication had restricted the use of methimazole during pregnancy, neverthe-
less, there is no definitive proof that MMI is actually responsible for the condition. 
Additional possible congenital malformation in children exposed to MMI during 
the first trimester of pregnancy are choanal and esophageal atresia, minor facial 
abnormalities and psychomotor delay, which either isolated or associated with 
aplasia cutis define the so called methimazole embryopathy [67, 77].
Because there are no reports of aplasia cutis in association with PTU, this drug 
is preferred by some physicians. Growing data from the literature for the causative 
roll of PTU for acute liver injury, had limited the use of the drug only during the 
first trimester of the pregnancy due to its lower risk for congenital malformations. 
Before pregnancy and during the second and third trimester methimazole is pre-
ferred, considered to be less hepatotoxic. Pregnancy itself does not appear to alter 
the maternal pharmacokinetics of MMI, although serum PTU levels may be lower in 
the latter part of gestation compared to the first and second trimesters [71].
The treatment of Graves’ disease during pregnancy should aim to achieve 
normalization of FT4 and FT3 levels with strict monitoring of maternal thyroid 
function at an appropriate intervals. Careful surveillance of fetal development 
to optimize fetal outcomes is also important, and this makes the team approach 
with a close collaboration between endocrinologist and obstetrician crucial. Apart 
from monitoring the laboratory parameters, there are clinical signs of improve-
ment, that include maternal weight gain, decrease in pulse rate and appropriate 
fetal growth, that should be followed up. Clinical signs and laboratory values must 
always be considered together when a therapeutic decision is necessary, and if for 
example, there is a detected lack of maternal weight gain in conjunction with mild 
elevations in thyroid hormone levels, the initiation of a low dose of ATD should be 
considered.
5.5.1.1 Antithyroid drugs: effect on the Fetus
In pregnancies complicated with concomitant Graves’ disease, fetal thyroid 
status is influenced by two maternal factors, both of which cross the placenta: 
maternal ATD dosage and maternal TRAb activity. There are two potentially 
opposing influences on fetal thyroid function by maternal TRAb, because they 
can be with either stimulating or blocking effect on the developing fetal thyroid 
gland. Different assays for maternal TRAb exist. Some, like one of the most 
commonly used radioreceptor assay does not distinguish between blocking and 
stimulating antibodies, so their peripheral effect can be estimated only by assess-
ing the thyroid function [79]. The currently available bioassay is the thyroid 
stimulating immunoglobulin (TSI), which measures the generation of cyclic 
adenosine monophosphate by cells that express TSH receptor when incubated 
with the patient’s serum [66].
Because both PTU and MMI can cross the placenta and they may decrease fetal 
thyroid hormone production The dose–response relationship between maternal 
ATD dose and neonatal thyroid function is controversial, as some studies have 
11
Graves’ Disease and Pregnancy
DOI: http://dx.doi.org/10.5772/intechopen.97640
reported a direct correlation [66, 69, 80] and others have not demonstrated this 
[64, 69, 73]. There are data showing that ATD drugs even at low daily dosages 
(PTU ≤ 100 mg, MMI ≤ 10 mg) at term may affect the fetal thyroid function. An 
elevated cord TSH level was found in 23% of babies born to such PTU-treated 
mothers and in 14% of those treated MMI [81]. There is an individual variability in 
serum PTU and MMI levels after a standard oral dose and that could partly explain 
the observed lack of correlation between maternal dosage and fetal thyroid func-
tion [81, 82]. Transplacental passage of maternal TRAb resulting in excessive fetal 
thyroid stimulation is the second factor that can influence fetal thyroid function. 
Usually, this becomes clinically relevant at 24 to 26 weeks, of gestation. Maternal 
levels reflect the degree of fetal exposure [83]. At term there is a strong correlation 
between maternal and cord TRAb levels with development of neonatal hyperthy-
roidism. Clinically relevant is to measure the maternal TRAb levels at term, because 
the combination of continued use of maternal ATD therapy with low maternal 
TRAb levels may lead to elevated serum TSH levels in approximately 50–60% of 
infants [80]. This shows how important is to adjust appropriately the maternal ATD 
dosage during pregnancy especially when maternal immune thyroid stimulation is 
low. In nonimmune types of thyrotoxicosis, like toxic adenoma for example, dose 
relationship between ATD and the risk of suppression of the fetal thyroid function 
is more profound, since there is no contribution of fetal thyroid stimulation by the 
maternal immune system. Therefore, it is not surprising that fetal thyroid status 
is not strictly correlated with maternal ATD dosage. Inappropriately high doses of 
ATD may result in development of fetal or neonatal goiter, which in the most severe 
cases if markedly enlarged at birth may cause respiratory distress. In the past, due 
to the concomitant iodide therapy and ATD, goiter occurred more frequently. The 
combined inhibitory effect on the fatal thyroid gland of iodide and ATD resulted 
in the development of goiter. One clinical approach is to perform a fetal utrasound 
in all women who are still taking relatively high ATD doses at 26 to 28 weeks (PTU 
≥450 mg/day, MMI ≥30 mg/day) [84]. If a fetal goiter is detected this could be due 
to either fetal hyperthyroidism, transplacental passage of stimulating TRAbs, or to 
fetal hypothyroidism caused by transplacental passage of maternal ATD therapy. 
In both situations intrauterine growth retardation may occur. The presence of fetal 
tachycardia (160–180 beats per minute) and advanced fetal bone age is highly 
suggestive of hyperthyroidism [85, 86]. When caused by maternal ATD use, a quick 
resolution within two weeks after birth of the neonatal goiter is observed, reflect-
ing the discontinuation of drug exposure [69]. Therefore, stopping maternal ATD 
therapy and monitoring the fetal goiter by ultrasound is advisable. Other thera-
peutic approach for treatment of the fetal goiter due to maternal ATD exposure 
includes intra-amniotic levothyroxine injections [87, 88], but because it was done 
concomitantly with lowering of the maternal PTU dose, it is difficult to estimate the 
relative importance of each factor on the resolution of the fetal goiter. The cessation 
of maternal ATD therapy alone may result in decrease in the fetal goiter assessed 
ultrasonographically [89]. Discontinuation or decreasing the dose of ATD therapy 
is crucial in cases where hypothyroidism is suspected because of transplacental 
ATD passage. Fetal goiter must be followed with sequential ultrasounds and if no 
reduction in size, within two to three weeks, occurs, fetal thyroid function should 
be determined by performing periumbilical blood sampling, and intra-amniotic 
levothyroxine therapy should considered if necessary. Several studies have reported 
no cognitive and somatic defects in development of children exposed to maternal 
ATD in utero [90–93] and this was so even after accounting for higher dosage or 
first trimester exposure. These were cross sectional studies that measured cognitive 
development by intelligence quotient. Therefore, it is unknown if transient, or more 




Considering the relation between thyroid hormones and sympathetic nervous 
system, beta-adrenergic blocking agents may be used transiently to control adren-
ergic symptoms, while waiting for ATD therapy to decrease thyroid hormone levels. 
The fact, that combined use of ATD and propranolol in comparison with ATD alone 
was related with a higher rate of spontaneous first trimester miscarriages, although 
the similar levels of thyroid hormone [94], beta-blockers should be used for short 
period and with caution.
5.5.3 Iodides
As was previously discussed, chronic use of iodides during pregnancy has been 
associated with hypothyroidism and goiter in neonates, sometimes in severe cases 
resulting in asphyxiation because of tracheal obstruction [95]. Iodides should not be 
used as a first line therapy in women with Grave’s because of the well-known dual 
effect of iodine upon the thyroid function and the risk for provocation of a latent 
autoimmune disorder and also for aggravation of the thyrotoxicosis increasing the 
iodine store in an already hyperfunctioning thyroid gland. Iodides could be used 
transiently if needed in preparation for thyroidectomy.
5.5.4 Surgery
Subtotal thyroidectomy for Graves’ disease is rarely considered during preg-
nancy. The reasons for such treatment could be the need to use high levels of ATD 
(PTU 450 mg/day, MMI 40 mg/day) to control the clinical symptoms and thyroid 
hormonal levels, if compressive symptoms due to goiter size develop or if a patient 
is allergic to ATD therapy or noncompliant to the therapeutic regiment. The surgery 
is usually performed in latter half of the second trimester. The surgery in the first 
trimester is relatively contraindicated, because that this is the time of the high-
est spontaneous abortion rate and surgery and anesthesia could possibly further 
increase the risk, but if clinically indicated subtotal thyroidectomy may be done in 
some specific cases [96].
5.5.5 131I therapy
The use of 131I therapy is completely contraindicated in pregnancy. The most 
vulnerable for the fetus period to 131I therapy is that after 12 weeks gestation, 
because at this period the fetal thyroid begins to concentrate radioiodine at 
higher rate than the maternal thyroid and other fetal tissues are generally more 
radiosensitive [97]. It is essentially important to exclude pregnancy in all women 
prior to radioiodine therapy. The therapeutic administration of 131I to a nurs-
ing mother is contraindicated and lactation should be stopped immediately if 
this occurs.
5.6 Lactation
Because the ATD present in breast milk in sufficient concentrations that can 
influence infant’s thyroid, their use in breast-feeding women was considered 
contraindicated. Due to the ability of PTU to bind more tightly with protein than 
MMI, less amount of PTU is available in the milk. The ratio of milk to serum 
levels is found to be lower for PTU (0.67) [98] than for MMI (1.0) [99], more-
over the amount of ingested drug secreted in breast milk is approximately six 
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times higher for MMI than for PTU (0.14 vs. 0.025% of the ingested dose) [99]. 
Despite this, the fetal thyroid function assessed in newborns breast-fed by moth-
ers treated with ATD with daily doses of PTU (50–300 mg), MMI (5–20 mg), or 
carbimazole (5–15 mg) for periods ranging from three weeks to eight months, 
remained normal, even in overtreated women with elevated serum TSH levels 
[100]. Data from the literature show that ATD therapy (PTU 300 mg/day, MMI 
20 mg/day) may be considered relatively safe during lactation [100]. Generally, 
PTU would be preferred than MMI, because of its less availability in breast milk. 
It is wise the drug to be taken by the mother after a feeding. So far, there are 
no reports of the development of ATD side-effects in an infant breast fed by a 
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